4 pages due by 20 hrs
Intravenous
| These equations are for reference only. You do not have to use them to complete your homework. But they help to understand the results! | |||||||||||||||||||||||||
| Plasma concentration (Cp) for one compartment model with iv bolus dosing and first order elimination | |||||||||||||||||||||||||
| Cp= (D/Vd)*exp(-ke*t) | |||||||||||||||||||||||||
| Equation for extension of duration of action | |||||||||||||||||||||||||
| Using the model in this worksheet, please answer the questions in the handout | Ci is the plasma concentration at a given time, assumed to be Ci>Ceff | ||||||||||||||||||||||||
| Please do not change any of the calculations | Delta teff is for how much longer the drug will be active (above Ceff) for a given half-life | ||||||||||||||||||||||||
| You only have to change some of the values of some of the parameters in bold red | This equation can be derived from the Cp(t) equation above | ||||||||||||||||||||||||
| This plot describes the plasma concentration (Cp) of an ideal drug after administration of an intravenous bolus | |||||||||||||||||||||||||
| (There are no drugs with this simple pharmacokinetic behavior, but it is a simple illustrative example) | |||||||||||||||||||||||||
| The drug is considered active in the patient if its plasma concentration is superior to a threshold value "Ceff" determined from previous clinical experience | |||||||||||||||||||||||||
| Parameter | Abbreviation | Units | Your Values | ||||||||||||||||||||||
| Elimination half-life | t1/2 (elim) | h | 10.0 | Same plot, with Y axis set to maximum Cp 10 ug/ml | |||||||||||||||||||||
| Dose | D | mg/person | 45 | ||||||||||||||||||||||
| Active plasma concentration threshold | Ceff | ug/ml | 3.0 | ||||||||||||||||||||||
| Don't touch these cells | |||||||||||||||||||||||||
| Elimination rate | ke | 1/h | 0.069 | ||||||||||||||||||||||
| Apparent volume of distribution | Vd | L/person | 14 | ||||||||||||||||||||||
| Threshold plot | Time (h) | Ceff (ug/ml) | |||||||||||||||||||||||
| 0 | 3.0 | ||||||||||||||||||||||||
| 25 | 3.0 | ||||||||||||||||||||||||
| Don't touch these cells | |||||||||||||||||||||||||
| Plot | |||||||||||||||||||||||||
| Time (h) | Cp (ug/ml) | ||||||||||||||||||||||||
| 0 | 3.2 | ||||||||||||||||||||||||
| 0.1 | 3.2 | ||||||||||||||||||||||||
| 0.25 | 3.2 | ||||||||||||||||||||||||
| 0.5 | 3.1 | ||||||||||||||||||||||||
| 1 | 3.0 | ||||||||||||||||||||||||
| 1.5 | 2.9 | ||||||||||||||||||||||||
| 2 | 2.8 | ||||||||||||||||||||||||
| 3 | 2.6 | ||||||||||||||||||||||||
| 4 | 2.4 | ||||||||||||||||||||||||
| 5 | 2.3 | ||||||||||||||||||||||||
| 6 | 2.1 | ||||||||||||||||||||||||
| 8 | 1.8 | ||||||||||||||||||||||||
| 10 | 1.6 | ||||||||||||||||||||||||
| 12 | 1.4 | ||||||||||||||||||||||||
| 14 | 1.2 | ||||||||||||||||||||||||
| 16 | 1.1 | ||||||||||||||||||||||||
| 18 | 0.9 | ||||||||||||||||||||||||
| 20 | 0.8 | ||||||||||||||||||||||||
| 22 | 0.7 | ||||||||||||||||||||||||
| 24 | 0.609 | ||||||||||||||||||||||||
| 26 | 0.5 | ||||||||||||||||||||||||
| 28 | 0.5 | ||||||||||||||||||||||||
| 30 | 0.4 | ||||||||||||||||||||||||
PK Intravenous Administration
Cp (ug/ml) 0 0.1 0.25 0.5 1 1.5 2 3 4 5 6 8 10 12 14 16 18 20 22 24 26 28 30 3.2142857142857144 3.1920830210476154 3.1590662096097355 3.104795342972718 2.9990346156540237 2.8968764869633832 2.7981982391661133 2.6108112740021858 2.435973053320283 2.2728432252424744 2.1206377137421519 1.8461223562452351 1.6071428571428572 1.3990991195830569 1.2179865266601415 1.060318856871076 0.92306117812261756 0.8035714285714286 0.69954955979152833 0.60899326333007087 0.53015942843553809 0.46153058906130884 0.40178571428571441 Ceff (ug/ml) 0 25 3 3
Time (h)
Cp (ug/ml)
PK Intravenous Administration
Cp (ug/ml) 0 0.1 0.25 0.5 1 1.5 2 3 4 5 6 8 10 12 14 16 18 20 22 24 26 28 30 3.2142857142857144 3.1920830210476154 3.1590662096097355 3.104795342972718 2.9990346156540237 2.8968764869633832 2.7981982391661133 2.6108112740021858 2.435973053320283 2.2728432252424744 2.1206377137421519 1.8461223562452351 1.6071428571428572 1.3990991195830569 1.2179865266601415 1.060318856871076 0.92306117812261756 0.8035714285714286 0.69954955979152833 0.60899326333007087 0.53015942843553809 0.46153058906130884 0.40178571428571441 Ceff (ug/ml) 0 25 3 3
Time (h)
Cp (ug/ml)
Subcutaneous
| CLRE-238 | Applied Translational Research | These equations are for reference only. You do not have to use them to complete your homework. But they help to understand the results! | ||||||||||||||||||
| Spring 2021 | ||||||||||||||||||||
| PK-PD Primer Homework | Plasma concentration (Cp) for one compartment model with sc bolus dosing and first order elimination | |||||||||||||||||||
| Date | 3/30/21 | |||||||||||||||||||
| Claudio D. Schteingart Ph.D. | ||||||||||||||||||||
| C(t) is Cp the plasma concentration as a function of time | ||||||||||||||||||||
| f is the bioavailability (scale 0 to 1) of the drug in the sc space | ||||||||||||||||||||
| Using the model in this worksheet, please answer the questions in the handout | ka is the absorption rate, ke is the elimination rate | |||||||||||||||||||
| Please do not change any of the calculations | D is the dose, Vd is the apparent volume of distribution | |||||||||||||||||||
| You only have to change some of the values of some of the parameters in bold red | ||||||||||||||||||||
| Equation for extension of duration of action | ||||||||||||||||||||
| Ci is the plasma concentration at a given time, assumed to be Ci>Ceff | ||||||||||||||||||||
| Delta teff is for how much longer the drug will be active (above Ceff) for a given half-life | ||||||||||||||||||||
| This equation can be used during the elimination phase of the above curve | ||||||||||||||||||||
| This plot describes the plasma concentration (Cp) of an ideal drug after administration of a subcutaneous bolus | ||||||||||||||||||||
| The drug is considered active in the patient if its plasma concentration is superior to a threshold value "Ceff" determined from previous clinical experience | ||||||||||||||||||||
| If the absorption half-life equals the elimination half-life the math fails (division by zero). If needed, enter a slightly different value, e.g. 3.99 or 4.01 instead of 4.00 | ||||||||||||||||||||
| Same plot, with Y axis set to maximum Cp 10 ug/ml | ||||||||||||||||||||
| Parameter | Abbreviation | Units | Your Values | |||||||||||||||||
| Absorption half-life | t1/2 (abs) | h | 9.00 | |||||||||||||||||
| Elimination half-life | t1/2 (elim) | h | 7.8 | |||||||||||||||||
| Dose | D | mg/person | 300 | |||||||||||||||||
| Active plasma concentration threshold | Ceff | ug/ml | 3.0 | |||||||||||||||||
| Don't touch these cells | ||||||||||||||||||||
| Subcutaneous bioavailability 0 to 1 | f | 1 | ||||||||||||||||||
| Apparent volume of distribution | Vd | L/person | 14 | |||||||||||||||||
| Absorption rate | ka | 1/h | 0.077 | |||||||||||||||||
| Elimination rate | ke | 1/h | 0.089 | |||||||||||||||||
| Multiplication factor | fDka/(Vd(Ka-ke)) | ug/ml | -139 | |||||||||||||||||
| Threshold plot | Time (h) | Ceff (ug/ml) | ||||||||||||||||||
| 0 | 3.0 | |||||||||||||||||||
| 26 | 3.0 | |||||||||||||||||||
| Don't touch these cells | ||||||||||||||||||||
| Plot | ||||||||||||||||||||
| Time (h) | Cp (ug/ml) | |||||||||||||||||||
| 0 | 0.00 | |||||||||||||||||||
| 0.1 | 0.16 | |||||||||||||||||||
| 0.25 | 0.40 | |||||||||||||||||||
| 0.5 | 0.79 | |||||||||||||||||||
| 1 | 1.52 | |||||||||||||||||||
| 1.5 | 2.19 | |||||||||||||||||||
| 2 | 2.80 | |||||||||||||||||||
| 2.5 | 3.35 | |||||||||||||||||||
| 3 | 3.86 | |||||||||||||||||||
| 3.5 | 4.32 | |||||||||||||||||||
| 4 | 4.74 | |||||||||||||||||||
| 5 | 5.45 | |||||||||||||||||||
| 6 | 6.02 | |||||||||||||||||||
| 7 | 6.47 | |||||||||||||||||||
| 9 | 7.04 | |||||||||||||||||||
| 11 | 7.30 | |||||||||||||||||||
| 13 | 7.31 | |||||||||||||||||||
| 15 | 7.14 | |||||||||||||||||||
| 17 | 6.86 | |||||||||||||||||||
| 19 | 6.50 | |||||||||||||||||||
| 21 | 6.09 | |||||||||||||||||||
| 23 | 5.65 | |||||||||||||||||||
| 24 | 5.43 | |||||||||||||||||||
| 25 | 5.21 | |||||||||||||||||||
| 26 | 4.99 | |||||||||||||||||||
| 27 | 4.77 |
PK Subcutaneous Administration
Cp (ug/ml) 0 0.1 0.25 0.5 1 1.5 2 2.5 3 3.5 4 5 6 7 9 11 13 15 17 19 21 23 24 25 26 27 0 0.16367190140838342 0.40412076579165146 0.79165592858399969 1.5190008883941082 2.1859595477621125 2.7962433329170779 3.3533613076132611 3.860630519029991 4.3211858354398114 4.7379892999460402 5.4513776389343889 6.0213625102136206 6.4662710223426938 7.0443072238819076 7.2953930015832285 7.3060037971859826 7.1437892527819962 6.8613160040050376 6.4991043312597387 6.0880874552893225 5.6515993222877396 5.4294186994073046 5.2069777995194295 4.9857184390268072 4.7668546007904764 Ceff (ug/ml) 0 26 3 3
Time (h)
Cp (ug/ml)
PK Subcutaneous Administration
Cp (ug/ml) 0 0.1 0.25 0.5 1 1.5 2 2.5 3 3.5 4 5 6 7 9 11 13 15 17 19 21 23 24 25 26 27 0 0.16367190140838342 0.40412076579165146 0.79165592858399969 1.5190008883941082 2.1859595477621125 2.7962433329170779 3.3533613076132611 3.860630519029991 4.3211858354398114 4.7379892999460402 5.4513776389343889 6.0213625102136206 6.4662710223426938 7.0443072238819076 7.2953930015832285 7.3060037971859826 7.1437892527819962 6.8613160040050376 6.4991043312597387 6.0880874552893225 5.6515993222877396 5.4294186994073046 5.2069777995194295 4.9857184390268072 4.7668546007904764 Ceff (ug/ml) 0 26 3 3
Time (h)
Cp (ug/ml)